News
10-14-2015, 10:23 PM
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July 31, 2015.
More... (http://www.news-medical.net/news/20151015/OncoSec-reports-net-loss-of-2465-million-for-fourth-quarter-of-fiscal-2015.aspx)
More... (http://www.news-medical.net/news/20151015/OncoSec-reports-net-loss-of-2465-million-for-fourth-quarter-of-fiscal-2015.aspx)